Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
CAS RN: 220904-83-6 | Product Number: G0609
GW-5074
Purity: >95.0%(HPLC)
- 3-(3,5-Dibromo-4-hydroxybenzylidene)-5-iodoindolin-2-one
Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
---|---|---|---|---|---|
100MG |
$207.00
|
Contact Us | Contact Us | 13 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
Product Number | G0609 |
Purity / Analysis Method | >95.0%(HPLC) |
Molecular Formula / Molecular Weight | C__1__5H__8Br__2INO__2 = 520.95 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
Store Under Inert Gas | Store under inert gas |
Condition to Avoid | Light Sensitive,Air Sensitive |
CAS RN | 220904-83-6 |
Reaxys Registry Number | 8641129 |
MDL Number | MFCD09971042 |
Appearance | White to Yellow powder to crystal |
Purity(HPLC) | min. 95.0 %(total of isomers) |
NMR | confirm to structure |
Melting Point | 262 °C |
RTECS# | NM3249100 |
HS Number | 2933.79.1500 |
References
- 1) The discovery of potent cRaf1 kinase inhibitors
- 2) Untying the regulation of the Raf-1 kinase (a review)
- 3) Structural model of the dimeric Parkinson’s protein LRRK2 reveals a compact architecture involving distant interdomain contacts
- 4) Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models
- 5) LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase
- 6) Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease (a review)
Articles/Brochures
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.